Drugs / staphylococcus albicans
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05543343 | Jan 2022 → Mar 2023 | chronic obstructive pulmonary disease | Qu Yiqing | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | staphylococcus albicans | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543343 ↗ |
| Modality | Other / unclassified | “different doses of bacterial lysates (Staphylococcus and Neisseria Tablets)” NCT05543343 ↗ |
| Route | Oral | “8 staphylococcus albicans tablets(0.3 mg) 3 times daily or 4 staphylococcus albicans tablets(0.3 mg)+4 placebo tablets 3 times daily” NCT05543343 ↗ |